A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. by Kadalayil, L et al.
8. Kwon HC, Roh MS, Oh SY et al Prognostic value of expression of ERCC1,
thymidylate synthase, and glutathione S-transferase P1 for 5-ﬂuorouracil/
oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 2007; 18:
504–509.
9. Boku N, Yamamoto S, Fukuda H et al Fluorouracil versus combination of irinotecan
plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3
study. Lancet Oncol 2009; 10: 1063–1069.
10. McShane LM, Altman DG, Sauerbrei W et al Reporting recommendations for tumor
marker prognostic studies (REMARK). J Natl Cancer Inst 2005; 97: 1180–1184.
11. Parker RJ, Eastman A, Bostick-Bruton F et al Acquired cisplatin resistance in
human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA
lesions and reduced drug accumulation. J Clin Invest 1991; 87: 772–777.
12. Satoh A, Toyota M, Itoh F et al Epigenetic inactivation of CHFR and sensitivity to
microtubule inhibitors in gastric cancer. Cancer Res 2003; 63: 8606–8613.
13. Smith S, Su D, Rigault de la Longrais IA et al ERCC1 genotype and phenotype in
epithelial ovarian cancer identify patients likely to beneﬁt from paclitaxel treatment
in addition to platinum-based therapy. J Clin Oncol 2007; 25: 5172–5179.
14. Mancuso A, Sacchetta S, Saletti PC et al Clinical and molecular determinants of
survival in pancreatic cancer patients treated with second-line chemotherapy:
results of an Italian/Swiss multicenter survey. Anticancer Res 2010; 30:
4289–4295.
15. Lord RV, Brabender J, Gandara D et al Low ERCC1 expression correlates with
prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell
lung cancer. Clin Cancer Res 2002; 8: 2286–2291.
16. Wilson MD, Ruttan CC, Koop BF et al ERCC1: a comparative genomic perspective.
Environ Mol Mutagen 2001; 38: 209–215.
17. Chen HY, Shao CJ, Chen FR et al Role of ERCC1 promoter hypermethylation in
drug resistance to cisplatin in human gliomas. Int J Cancer 2010; 126:
1944–1954.
18. Carethers JM, Chauhan DP, Fink D et al Mismatch repair proﬁciency and in vitro
response to 5-ﬂuorouracil. Gastroenterology 1999; 117: 123–131.
19. An C, Choi IS, Yao JC et al Prognostic signiﬁcance of CpG island methylator
phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res
2005; 11: 656–663.
20. Locker GY, Hamilton S, Harris J et al ASCO 2006 update of recommendations for
the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24:
5313–5327.
21. Smorenburg CH, Peters GJ, van Groeningen CJ et al Phase II study of tailored
chemotherapy for advanced colorectal cancer with either 5-ﬂuouracil and
leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate
synthase and dihydropyrimidine dehydrogenase. Ann Oncol 2006; 17:
35–42.
22. Scartozzi M, Loretelli C, Berardi R et al Phase II study of pharmacogenetic-tailored
therapy in elderly colorectal cancer patients. Dig Liver Dis 2012; 44: 74–79.
23. Grem JL, Danenberg KD, Behan K et al Thymidine kinase, thymidylate
synthase, and dihydropyrimidine dehydrogenase proﬁles of cell lines of the
National Cancer Institute’s Anticancer Drug Screen. Clin Cancer Res 2001; 7:
999–1009.
Annals of Oncology 24: 2565–2570, 2013
doi:10.1093/annonc/mdt247
Published online 14 July 2013
A simple prognostic scoring system for patients
receiving transarterial embolisation for hepatocellular
cancer
L. Kadalayil1, R. Benini2, L. Pallan3, J. O’Beirne4, L. Marelli4, D. Yu5, A. Hackshaw1, R. Fox6,
P. Johnson3, A. K. Burroughs4, D. H. Palmer3,† & T. Meyer2,7,†
1Cancer Research UK & UCL Cancer Trials Centre, London; 2Department of Oncology, UCL Medical School, Royal Free Campus, London; 3Cancer Research UK Institute
for Cancer Studies, University of Birmingham; 4The Royal Free Sheila Sherlock Liver Centre, Royal Free Hospital, London; 5Department of Radiology, Royal Free Hospital,
London; 6Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham; 7UCL Cancer Institute, London, UK
Received 13 January 2013; revised 9 April 2013; accepted 23 May 2013
Background: The prognosis for patients with hepatocellular cancer (HCC) undergoing transarterial therapy (TACE/TAE)
is variable.
Methods:We carried out Cox regression analysis of prognostic factors using a training dataset of 114 patients treated
with TACE/TAE. A simple prognostic score (PS) was developed, validated using an independent dataset of 167 patients
and compared with Child–Pugh, CLIP, Okuda, Barcelona Clinic Liver Cancer (BCLC) and MELD.
Results: Low albumin, high bilirubin or α-fetoprotein (AFP) and large tumour size were associated with a two- to
threefold increase in the risk of death. Patients were assigned one point if albumin <36 g/dl, bilirubin >17 μmol/l, AFP
>400 ng/ml or size of dominant tumour >7 cm. The Hepatoma arterial-embolisation prognostic (HAP) score was
calculated by summing these points. Patients were divided into four risk groups based on their HAP scores; HAP A, B, C
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and D (scores 0, 1, 2 and >2, respectively). The median survival for the groups A, B, C and D was 27.6, 18.5, 9.0 and 3.6
months, respectively. The HAP score validated well with the independent dataset and performed better than other
scoring systems in differentiating high- and low-risk groups.
Conclusions: The HAP score predicts outcomes in patients with HCC undergoing TACE/TAE and may help guide
treatment selection, allow stratiﬁcation in clinical trials and facilitate meaningful comparisons across reported series.
Key words: embolization, hepatocellular, prognosis
introduction
Hepatocellular cancer (HCC) is the sixth most common cancer
worldwide and third most common cause of cancer mortality.
Unfortunately, the majority of patients have unresectable
disease at presentation, and transarterial chemoembolization
(TACE) or bland embolisation (TAE) has been widely used in
these cases. Two small, randomised trials and a meta-analysis
[1] have demonstrated a survival advantage in carefully selected
patients treated with TACE compared with best supportive care,
but TACE has not yet been shown to be superior to TAE [2].
Recent guidelines, recommended TACE for patients with
intermediate-stage HCC according to the BCLC classiﬁcation
which accounts for ∼20% of patients [3]. However, the
intermediate group comprises a wide spectrum in terms of liver
function and extent of tumour, and this may explain the large
differences in survival reported for individual series [4].
A simple, pragmatic and reliable prognostic index based on
objective measures would be of value in providing information
to patients, for stratifying patients entering clinical trials and in
making meaningful comparisons between series reported in the
literature.
The aims of our study were (i) to identify predictors of
survival in a cohort of patients undergoing TACE or TAE for
unresectable HCC, (ii) to develop and validate a simple scoring
system and (iii) to compare the new scoring system with the
most frequently used prognostic systems for its ability to
separate high- and low-risk patients.
methods and materials
study population
We reviewed 114 sequential patients with HCC treated with TAE/TACE at
the Royal Free Hospital and University College Hospital between 1997 and
2010, including patients from a recently reported clinical trial [2]. HCC was
diagnosed by histology or imaging according to European Association for
the Study of the Liver criteria and patients who had surgery or
transplantation were excluded. These patients formed the ‘training dataset’,
used to develop the hepatoma arterial-embolisation prognostic (HAP) score.
The HAP score was validated using an external and independent cohort
of 167 patients treated with TACE at University Hospital Birmingham NHS
Trust (the ‘validation dataset’). Both the centres are liver transplant centres,
and TAE/TACE was deemed to be the appropriate treatment modality by a
multidisciplinary team.
treatment procedure
In the training dataset, TAE-treated patients were embolised with polyvinyl
alcohol (PVA) particles (50–150 µm) alone, while TACE-treated patients
received either transarterial epirubucin mixed with lipiodol or cisplatin
before embolization. In the validation dataset, all patients were treated with
TACE based on doxorubicin (Adriamycin) and lipiodol, and PVAwas used
as the embolic particle. TACE/TAE was repeated thereafter if tumour
vascularity persisted, provided the patient tolerated the procedure and there
were no emergent contraindications.
statistical analysis
Overall survival (OS) was measured from the date of ﬁrst TACE/TAE until
death or the date of last follow-up. Univariable and multivariable Cox
regression were used to produce crude and adjusted hazard ratios (HRs)
and their 95% conﬁdence intervals (95% CI) for potential risk factors.
All factors were included in a stepwise backward selection model (with a
P value of ≤0.10) to identify a set of factors that together have the best
performance. The proportionality assumption was checked using
Schoenfeld residuals of the ﬁnal model. Tumour size and the three
biochemical factors [albumin, bilirubin and α-fetoprotein (AFP)],
although continuous, were used as binary variables in the Cox models
for ease of interpretation of the HRs and application in clinical practice.
The cut-offs used were bilirubin 17 μmol/l, albumin 36 g/dl which
are, respectively, the upper and lower limits of the normal range; AFP:
400 ng/ml since this has been used as a diagnostic cut-off, and 7 cm for
tumour size.
The HAP score was developed using the set of clinical factors that had the
best prognostic performance from the multivariable analysis. The minimum
follow-up for each patient was 6 months. OS was estimated using the
Kaplan–Meier method, and statistical signiﬁcance tested using the log-rank
test. All statistical analyses were carried out using Stata 12. All reported
P values are two-sided.
comparison of different scoring systems to predict
mortality
training dataset. Using three different methods, we compared the HAP
score with ﬁve well-known scoring systems; two scores of liver function:
Child–Pugh and Model of End-Stage Liver Disease (MELD), and three
scores which include both liver function and tumour characteristics:
Okuda [5], Cancer of Liver Italian Programme (CLIP) [6] and BCLC [7].
Initially, we compared the HRs estimated for each of the scores using Cox
regression. We then compared the Area Under the Receiver Operating
Characteristic (AUROC) curves in order to evaluate the discriminatory
ability of these scoring systems to predict OS. Finally, we compared the
estimates of the detection rates (DRs) and false-positive rates (FPRs) for
death for HAP with the ﬁve existing scoring systems in order to evaluate its
performance relative to the other ﬁve scoring systems. Ninety-ﬁve percent
conﬁdence intervals (CIs) for DR and FPR were estimated using the
Wilson method.
original articles Annals of Oncology
 | Kadalayil et al. Volume 24 | No. 10 | October 2013
 at U
CL Library Services on July 25, 2014
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
results
patients
The training and validation sets were similar with respect to
most variables (Table 1). The training cohort had a higher
proportion of Child–Pugh score B patients, and more patients
with a MELD >10. Main-branch portal vein thrombosis was an
exclusion criterion for TAE/TACE in both institutions, but
segmental portal vein involvement was more common in the
validation dataset.
At the time of the analysis, 89 of 114 in the training cohort
and 107 of 167 in the validation cohort had died. The median
OS was 15.0 (95% CI 9.7–16.6) and 13.7 (95% CI 9.4–16.9)
months for the training and validation cohorts, respectively.
The median follow-up was 5.7 (95% CI 2.5–6.8) and 1.9 (95%
CI 1.2–2.5) years for the two cohorts.
univariable and multivariable cox regression analyses. In both
univariable and multivariable analyses, tumour size, albumin,
bilirubin and AFP were statistically signiﬁcant predictors
of OS (Table 2). Tumour size was divided into four groups
(<3 cm, 3–5 cm, 5–7 and >7 cm). The ﬁrst three groups were
very similar in their survival outcomes in a univariable
analysis, whereas the survival outcome of the group with
lesions >7 cm was signiﬁcantly different from the group
with lesion size <3 cm (P = 0.008). Therefore, the groups with
lesion size ≤7 cm were combined and compared with the
group with >7 cm. The Kaplan–Meier OS curves for these
four factors are shown in supplementary Figure S1, available
at Annals of Oncology online. Although the adjusted HR
for creatinine was statistically signiﬁcant, the effect was small
(only 2% decrease in risk for an increase of 1 μmol/l
creatinine).
developing the prognostic score. The HAP scoring system was
based on the four most statistically signiﬁcant predictors of OS
in the multivariable analysis; albumin, bilirubin, AFP and
tumour size. Patients were assigned one point for each of the
four parameters when they were in the adverse group as deﬁned
by the cut-off. The HAP score was deﬁned as the sum of these
scores, and patients were classiﬁed into low- (HAP A),
intermediate-(HAP B), high-(HAP C) or very high-(HAP D)
risk groups with HAP scores of 0, 1, 2 or >2 points, respectively
(Table 3). The equal weighting applied to each factor was
justiﬁed since the adjusted HRs for the four factors were similar
in a multivariable model using just these four factors
(supplementary Table S1, available at Annals of Oncology
online).
The HAP score could be calculated for 91 patients in the
training set and 151 in the validation set (supplementary
Table S2, available at Annals of Oncology online). Kaplan–Meier
plots stratiﬁed by the HAP score showed statistical evidence for
a reduction in OS when moving from HAP A to HAP D in both
training and validation sets (P value from the log-rank test:
<0.001, Figure 1).
comparison of different scoring systems. The Child–Pugh,
Okuda, CLIP, BCLC and HAP scoring systems, but not MELD,
were found to be statistically signiﬁcant in univariable analyses
using the training dataset (supplementary Table S3, available at
Annals of Oncology online). HRs were the largest for HAP
groups C (HR 4.4) and D (HR 10.11) than any other scoring
system.
Table 1. Demographic data for hepatocellular carcinoma (HCC) patients
treated with transarterial chemoembolization or bland embolisation
(TACE/TAE)
Characteristics Training dataset Validation dataset
N (%) Total
(N)
N (%) Total
(N)
Age at ﬁrst session, years
(median, range)
65 (23–84) 114 64 (18–80) 166
Gender (female/male) 15/99 (13/87) 114 34/133 (20/80) 167
Aetiology 106 167
Hepatitis B virus (HBV) 17 (16) 16 (10)
HCV 27 (25) 26 (16)
Alcohol-related 16 (15) 42 (25)
Other 46 (43) 83 (50)
Child–Pugh class 114 167
A 81 (71) 151 (90)
B 30 (26) 16 (10)
C 3 (3) 0
CLIP score 96 153
0 17 (18) 21 (14)
1 44 (46) 58 (38)
2 26 (27) 41 (27)
>2 9 (9) 33 (22)
Okuda stage 89 155
1 59 (66) 106 (68)
>1 30 (34) 49 (32)
MELD score 95 167
≤10 37 (39) 136 (81)
>10 58 (61) 31 (19)
BCLC stage 113 - -
A 39 (35)
B 35 (31)
C 35 (31)
D 4 (4)
Tumour characteristics
Tumour size (mm) 112 154
≤30 25 (22) 22 (14)
30–50 34 (32) 54 (35)
50–70 18 (17) 32 (21)
>70 32 (29) 46 (30)
Tumour volume > 50% 7 (6) 108 36 (23) 156
Number of lesions 113 161
1 48 (42) 59 (37)
≥2 65 (56) 102 (63)
α-Fetoprotein (ng/ml) 102 163
≤400 70 (69) 113 (69)
>400 32 (31) 50 (31)
Presence of ascites 18 (17) 103 7 (4) 159
Segmental portal vein
thrombosis
7 (6) 114 47 (28) 167
Treatment 114 167
TAE 56 (49) NA
TACE 49 (43) 167 (100)
TAE + TACE 9 (8) NA
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As with the training dataset, univariable analyses for Child–
Pugh, Okuda, CLIP, MELD and HAP using the validation
dataset revealed the strongest association between the HAP
scoring system and survival (supplementary Table S3, available
at Annals of Oncology online, HR: 2.45 and 3.54 for HAP groups
C and D, respectively). BCLC could not be calculated for the
validation dataset since the performance status was not available
for these patients.
The discriminatory ability of the various scoring systems to
predict mortality was evaluated separately using both the
training and validation datasets by comparing the AUROC
curve. The analyses were carried out at 1 and 2 years after the
ﬁrst TACE/TAE treatment (supplementary Table S4, available at
Annals of Oncology online). In the training cohort, the HAP
scoring system had the highest AUROC at both time points.
We compared the AUROC of HAP with each of Child–Pugh,
Okuda, CLIP, BCLC and MELD in a pairwise manner
(supplementary Table S5, available at Annals of Oncology
online). The difference was statistically signiﬁcant at 1 year
(P≤ 0.01) for Okuda, CLIP, BCLC and MELD, and close to
signiﬁcance for Child–Pugh. At 2 years, and the difference was
signiﬁcant for Okuda, MELD, BCLC and Child–Pugh, but not
so for CLIP. These results combined with the highest AUROC
for HAP (supplementary Table S4, available at Annals of
Oncology online) suggest HAP as a better scoring system than
Child–Pugh, Okuda, BCLC and MELD at 1 and 2 years, and
that HAP is better than CLIP at 1 year and is at least as good at
2 years.
Area under the ROC curve was also the highest for HAP at 1
year in the validation dataset (P = 0.02, supplementary Table S4,
available at Annals of Oncology online). Moreover, pairwise
Table 2. Cox regression analysis of potential risk factorsa
Risk factors Univariable Multi variable
HR (95%CI) P value No. of deaths/patients bAdjusted HR (95% CI) P value
Age at 1st session 0.999 (0.98, 1.02) 0.94 89/114 1.02 (0.99, 1.05) 0.13
Aetiology 0.04 0.40
Hepatitis B virus (HBV) 1 16/17 1
HCV 0.63 (0.33, 1.24) 19/27 0.60 (0.26, 1.38)
ALD 0.32 (0.15, 0.72) 10/16 0.35 (0.11, 1.14)
Multiple 0.59 (0.33, 1.06) 38/46 0.52 (0.23, 1.16)
Creatinine (μmol/l) 0.99 (0.98, 1.002) 0.13 81/106 0.98 (0.97, 0.999) 0.02
INR 0.09 0.33
≤1.2 1 42/57 1
>1.2 1.48 (0.94, 2.32) 36/46 1.44 (0.75, 2.77)
Bilirubin (μmol/l) 0.04 0.047
≤17 1 26/38 1
>17 1.66 (1.02, 2.71) 47/59 2.21 (1.07, 4.56)
Albumin (g/dl) 0.002 0.004
≥36 1 47/64 1
<36 2.08 (1.31, 3.30) 34/42 3.03 (1.62, 5.69)
α-Fetoprotein (AFP, ng/ml) <0.001 <0.001
≤400 1 50/70 1
>400 2.89 (1.76, 4.73) 27/32 2.50 (1.24, 5.04)
Number of lesions 0.15 0.14
1 1 37/48 1
2 0.97 (0.54, 1.75) 16/21 1.07 (0.50, 2.32)
>2 1.56 (0.96, 2.54) 35/44 2.18 (1.07, 4.44)
Size of the largest lesion (mm) <0.001 0.001
≤70 1 59/77 1
>70 2.56 (1.55, 4.22) 25/32 2.51 (1.22, 5.19)
ALD, alcoholic liver disease.
aFor patients in the training dataset.
bAdjusted for age, treatment, aetiology, creatinine, INR, albumin, AFP, number of lesions and tumour size. The multivariate analysis was based on 81 patients
with 59 deaths.
Table 3. Calculation of the Hepatoma arterial-embolisation prognostic
(HAP) score
Prognostic factor Points
Albumin < 36 g/dl 1
AFP > 400 ng/ml 1
Bilirubin > 17 μmol/l 1
Maximum tumour diameter >7 cm 1
HAP classiﬁcation Points
HAP A 0
HAP B 1
HAP C 2
HAP D >2
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comparisons indicate that the HAP area is signiﬁcantly different
from Okuda, MELD and Child–Pugh at 1 year (supplementary
Table S5, available at Annals of Oncology online). ROC curves
show that for a given value of sensitivity, the HAP scoring
system had the lowest false-positive rate (FPR) among all the
scoring systems considered with both datasets (data not shown).
Taken together our results show better performance for HAP
when compared with Okuda, MELD, BCLC and Child–Pugh
and at least as good a performance as CLIP (supplementary
Tables S4 and S5, available at Annals of Oncology online).
Supplementary Table S6, available at Annals of Oncology
online, shows the DRs, FPRs and likelihood ratio (LR) for each
scoring method. The LR combines DR and FPR, and the larger
the value, the better the prognostic performance. The HAP
scoring system had the highest LR at a cut-off of ≥3 (LR = 4.71),
with DR = 33% (i.e. a third of patients dying at 1 year had a
HAP score≥ 3), and FPR = 7% (i.e. 7% of those alive at 1 year
have HAP≥ 3). A HAP score≥ 3 corresponds to the very high
risk group (HAP D). The LR for the highest risk groups for
Child–Pugh, Okuda, CLIP, MELD and BCLC were 3.14, 2.89,
1.86, 2.86 and 1.29 respectively. Furthermore, although the LRs
were similar for HAP≥ 2 and Okuda ≥1 at 1 year (2.23 versus
2.32) the DR for Okuda ≥ 1 was much lower than that of HAP
(78% for HAP and 51% for Okuda).
The HAP scoring system performed similarly with the
validation dataset with the highest LR for HAP≥ 3 out of all the
scoring systems considered, except for Okuda (supplementary
Table S7, available at Annals of Oncology online).
discussion
Several staging systems have been developed for the
classiﬁcation of patients with HCC, but none have been
speciﬁcally developed to predict outcomes of therapy for HCC.
Previous studies have compared staging systems for their ability
to predict the survival of patients treated with TACE, but there
is no consensus as to which is best [8–13]. Moreover, these
systems cover the whole clinical spectrum of HCC and are not
ideally suited to the TACE-treated subgroup that may fall into a
limited range within these classiﬁcations.
Against this background, we identiﬁed key independent
prognostic factors among 114 sequential TAE/TACE-treated
patients. Using four factors (albumin, bilirubin, AFP and
tumour size) most strongly predictive of survival, we derived a
clinical score that stratiﬁes patients into low-, intermediate-,
high- and very high-risk groups. The risk factors included in the
HAP score are consistent with previous studies. AFP, which
may represent a surrogate marker for either tumour bulk or
aggressive tumour biology, has frequently emerged as signiﬁcant
in other studies [9,14,15]. Consistent with the ﬁndings of Llado
et al. [16], we found that AFP levels >400 ng/ml were associated
with a threefold increase in the risk of death. Albumin is an
index of liver function and parenchymal reserve and has also
been identiﬁed as prognostic in other studies [15,16]. Tumour
size had consistently been shown to inﬂuence survival with a
larger tumour volume being associated with higher risk of
vascular invasion and distant metastasis [14–17]. The threshold
above which survival is reduced has varied between 3 and 10
cm, and there is no consensus on which size cut-off should be
used [14,15,17–19]. In the present study, patients with largest
lesion >7 cm had double the risk of death and 60% reduction in
median survival compared with those in whom it was ≤7 cm.
Our analyses suggest that the HAP scoring system predicts
survival in TAE/TACE-treated patients better than other scoring
systems which have been applied in this population, including
Child–Pugh, Okuda, CLIP, BCLC and MELD [8]. Univariable
Cox models, examining the association between each of the six
scoring systems and survival, produced the largest HRs for HAP
and, secondly, the HAP scoring system had the greatest
discriminatory ability to predict mortality; it had the highest
AUROC and the highest LR, when examining DRs and FPRs.
Alternative prognostic indices have been proposed for TACE
patients but suffer from limitations that render them less
practical than the HAP score. The index reported by Llado et al.
Figure 1. Kaplan–Meier survival curves according to the Hepatoma arterial-embolisation prognostic (HAP) score in the training dataset (A) and the
validation dataset (B). For the training dataset, the median overall survival (OS) times were 27.6 months (95% CI16 to not estimable), 18.5 months (95%
CI15.5–30.4), 9.0 months (95% CI 6.9–15.4) and 3.6 months (95% CI 1.7–8.5) for HAP A, B, C and D, respectively. For the validation set, OS median values
were 25.5 (95%CI 13.7–32.8), 18.1 (95% CI 9.9 to not estimable), 8.9 (95% CI 6.8–16.1) and 5.9 (95% CI 2.8–12.7) months, respectively.
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[16] was mathematically more complex and requires the
assessment of greater or less than 50% tumour burden in
contrast to a simple unidimensional measurement. In another
score, the assessment of iodised oil uptake was required but is
not applicable with the increasing use of drug-eluting beads that
obviate the need for lipiodol [17]. Prognostic indicators that rely
on some form of post-embolisation assessment have also been
deﬁned, but these are not helpful in pre-selection of patients
[20,21].
The implementation and practice of TACE are highly variable
between institutions [22], and validation of the HAP score with
an independent data set was required to ensure that the score
was broadly applicable. It is reassuring that the HAP score was
equally discriminatory in the validation cohort despite
differences in technique, chemotherapy and patient
characteristics. In both the cohorts, a HAP score of C or D
deﬁned poor prognosis groups which are unlikely to have
beneﬁted from TACE and might now be better served with
systemic therapy or supportive care. Overall, the clinical
outcomes for these datasets was remarkably similar reﬂecting
common selection criteria, but the application of the HAP score
may also help in making meaningful comparisons between
published series in which outcomes are more divergent.
In summary, we have deﬁned a simple and clinically relevant
prognostic index requiring the measurement of two tumour
variables and two liver variables, speciﬁcally for patients
undergoing TACE. The score performed well against other
prognostic staging systems for HCC despite its simplicity, and
has been validated on an independent dataset, but it is
appropriate to prospectively validate it on a larger cohort to
conﬁrm our ﬁndings.
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